Trial Profile
An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 17 Oct 2014 New trial record